Viral Protein Patents (Class 536/23.72)
-
Publication number: 20140162340Abstract: Synthetic representative HCV subtypes, including a 1a and 1b genome, dubbed Bole1a and Bole1b, are provided using an inventive method of Bayesian phylogenetic tree analysis, ancestral sequence reconstruction and covariance analysis. Bole1a branches centrally among 390 full-genome sequences used in its design, a carefully curated 143 sequence full-genome dataset, and separate genomic regions including an independent set of 214 E1E2 sequences from a Baltimore cohort. Bole1a is phylogenetically representative of widely circulating strains. Full genome non-synonymous diversity comparison and 9-mer peptide coverage analysis showed that Bole1a is able to provide more coverage (94% and 78% respectively) than any other sequence in the dataset including H77, a traditional reference sequence. Bole1a also provides unsurpassed epitope coverage when compared to all known T cell epitopes.Type: ApplicationFiled: May 2, 2012Publication date: June 12, 2014Inventors: Stuart Campbell Ray, Supriya Munshaw, Lin Liu
-
Publication number: 20140161771Abstract: Disclosed are compositions and methods comprising one or more recombinant influenza viruses. Recombinant influenza viruses with mutated polymerases and/or rearranged genomes are disclosed. Constructs comprising different influenza nucleic acid sequences are also provided. Methods of inducing protecting immunity with the recombinant influenza viruses are disclosed. Also disclosed are methods of plasmid-free production of influenza virus comprising amplicons comprising one or more of influenza genes.Type: ApplicationFiled: May 28, 2013Publication date: June 12, 2014Inventors: Daniel R. Perez, Hongjun Chen, Yibin Cai, Lindomar Jose Pena, Matthew Angel
-
Publication number: 20140161833Abstract: The invention relates to methods and compositions for preventing or treating human rhinovirus infection.Type: ApplicationFiled: February 18, 2014Publication date: June 12, 2014Applicant: Sanofi Pasteur Biologics, LLCInventors: Kirill KALNIN, Yanhua Yan, Harold Kleanthous
-
Patent number: 8748127Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.Type: GrantFiled: May 29, 2008Date of Patent: June 10, 2014Assignees: Xiamen University, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.Inventors: Shaowei Li, Huirong Pan, Bo Liu, Jun Zhang, Ji Miao, Ningshao Xia
-
Patent number: 8747859Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.Type: GrantFiled: February 20, 2009Date of Patent: June 10, 2014Assignees: The United States of America, as Represented by the Secretary of Agriculture, Boehringer Ingelheim Vetmedica, Inc.Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Mike Roof, Kelly Burkhart, David E. Gorcyca
-
Patent number: 8748591Abstract: The present invention discloses a chimeric alphavirus comprising a Sindbis virus cDNA fragment, an Eastern equine encephalitis virus cDNA fragment, a Western equine encephalitis virus cDNA fragment or a combination thereof. The present also discloses the use of this chimeric alphavirus as vaccines and in serological and diagnostic assays.Type: GrantFiled: April 17, 2008Date of Patent: June 10, 2014Assignee: The Board of Regents of the University of Texas SystemInventors: Scott C. Weaver, Ilya Frolov
-
Patent number: 8748088Abstract: Provided herein are methods for detecting the presence of replication-competent HIV-1 virus in a subject who is being treated with an intensified highly active anti-retroviral therapy (HAART) regimen. These methods comprise selecting a subject who is being treated with an intensified HAART regimen including an integration inhibitor; obtaining a sample, e.g., a blood sample, from a subject; specifically amplifying a segment spanning two-long terminal repeat (2-LTR) junction of 2-LTR circles using PCR to determine the level of 2-LTR circles in the sample; and determining the presence of replication competent virus based on the level of 2-LTR circles in the sample. These methods can also be used to monitor an intensified HAART regimen by obtaining samples from the same subject at different time points during the HAART treatment, and comparing levels of the 2-LTR circles in those samples.Type: GrantFiled: January 29, 2010Date of Patent: June 10, 2014Assignee: University of MassachusettsInventor: Mario Stevenson
-
Publication number: 20140155476Abstract: A recombinant vector comprises simian adenovirus SAdV-39, -25.2, -26, -30, -37, and -38 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-39, -25.2, -26, -30, -37, and -383 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.Type: ApplicationFiled: February 12, 2014Publication date: June 5, 2014Applicant: The Trustees of the University of PennsylvaniaInventors: Soumitra Roy, James M. Wilson, Luk H. Vandenberghe
-
Publication number: 20140154283Abstract: Described herein is the identification and of a potent West Nile virus (WNV) CD4 positive T cell epitope and its use for increasing the immunogenicity of heterologous flavivirus vaccines, such as dengue virus type 2 (DENV-2) DNA and virus-like particle (VLP) vaccines. Also described are methods for the identification of potent T cell epitopes to enhance immunogenicity of multivalent vaccines.Type: ApplicationFiled: July 11, 2012Publication date: June 5, 2014Applicants: Department of health and Human ServicesInventors: Gwong-Jen J. Chang, Holly R. Hughes
-
Patent number: 8741309Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.Type: GrantFiled: July 24, 2006Date of Patent: June 3, 2014Assignees: The United States of America as represented by the Secretary of Agriculture, Boehringer Ingelheim Vetmedica, Inc.Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Mike Roof, Kelly Burkhart, David E. Gorcyca
-
Publication number: 20140147459Abstract: Described herein is the generation of optimized H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H1N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on selected H1N1 viruses isolated from 1918-2012. Provided herein are optimized H1N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.Type: ApplicationFiled: November 27, 2013Publication date: May 29, 2014Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Ted M. Ross, Corey J. Crevar, Donald M. Carter, JR.
-
Publication number: 20140147460Abstract: The present invention relates to a truncated L1 protein of Human Papillomavirus (HPV) Type 33, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein and the virus-like particle are useful for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer. The invention also relates to the use of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer.Type: ApplicationFiled: May 22, 2012Publication date: May 29, 2014Applicants: XIAMEN INNOVAX BIOTECH CO. LTD., XIAMEN UNIVERSITYInventors: Shaowei Li, Xianglin Kong, Minxi Wei, Huirong Pan, Jun Zhang, Ningshao Xia
-
Publication number: 20140147458Abstract: The present invention relates to novel Varicella-zoster virus strain and to a chicken pox and herpes zoster virus vaccine using the same. More particularly, the present invention relates to genome DNA of VZV MAV/06 strain isolated from a Korean patient, to an open reading frame (ORF) thereof, to a protein coded by the genome DNA of VZV MAV/06 strain and the ORF thereof, and to a vaccine composition which contains the protein as an active ingredient.Type: ApplicationFiled: February 24, 2012Publication date: May 29, 2014Applicant: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTEInventors: Geun Hee Kim, Shi Nae Kwon, Chan Hee Lee, Yeop Yoon
-
Publication number: 20140148586Abstract: Described herein is a soluble HIV-1 retrovirus transmembrane glycoprotein gp41 trimer (Soc-gp41M-Fd) containing a partial ectodomain and the cytoplasmic domain, that is fused to the small outer capsid (Soc) protein of bacteriophage T4 and the Foldon domain of the bacteriophage T4 fibritin (Fd). The gp41 trimer that has a prehairpin structure could be utilized to understand the mechanism of viral entry and as a candidate for development of HIV-1 vaccines, diagnostics and therapeutics. Other secondary embodiments of the gp41 proteins containing different modifications are also disclosed. According to one embodiment, the gp41 trimer is further attached to a cell penetration peptide (CPP). Methods of producing gp41 trimers are also disclosed.Type: ApplicationFiled: November 27, 2013Publication date: May 29, 2014Applicant: THE CATHOLIC UNIVERSITY OF AMERICAInventors: Venigalla B. RAO, Guofen GAO
-
Patent number: 8734808Abstract: Vaccines preparations against canine parvovirus are provided. The vaccines include a novel canine parvovirus-2 isolated from a raccoon, and related nucleic acids and proteins.Type: GrantFiled: October 14, 2010Date of Patent: May 27, 2014Assignee: The Board of Regents for Oklahoma State UniversityInventor: Sanjay Kapil
-
Patent number: 8735561Abstract: Five optimized genes of capsid L1 protein from human papillomavirus type 16, 58, 18, 6 and 11, which are modified by using insect's preferred codons and so on. Method for modifying those genes to express more highly in insect cells. Virus-like particle's vaccine compositions comprising HPV L1 proteins or their functional relatives produced by using those modified genes. Those optimized genes of L1 can be used to produce HPV 16 VLP, HPV 58VLP, HPV 18VLP, HPV 6 VLP, HPV 11VLP in insect cells. Yields of virus-like particles derived from those optimized HPV L1 genes are high. Mixed multivalent vaccines comprising above optimized HPV L1 genes can be used to prevent and treat multiple HPV infection and diseases related with it.Type: GrantFiled: September 18, 2007Date of Patent: May 27, 2014Assignee: Chinese Academy of Medical Sciences, Institute of Basic Medical SciencesInventors: Xuemei Xu, Ting Zhang, Yufei Xu, Dongsheng Fan
-
Patent number: 8729231Abstract: The disclosure relates, in some embodiments, to sequences of a novel mutant or variant of the hepatitis B surface antigen (HBsAg) and methods for detecting this genome and protein variant, and antibodies directed against it, from patients' samples.Type: GrantFiled: December 16, 2008Date of Patent: May 20, 2014Assignee: Siemens Healthcare Diagnostics Products GmbHInventors: Delia Bussfeld, Anne-Sophie Endres, Helga Meisel, Michael Weik
-
Patent number: 8728484Abstract: The present invention includes polypeptides, polynucleotides, antibodies, and vaccines associated with Runting Stunting Syndrome (RSS) in poultry. The present invention also includes diagnostic methods based on such polypeptides, polynucleotides, and antibodies and methods of protecting poultry, including chickens, against RSS by the administration of such polypeptides, polynucleotides, antibodies, and vaccines.Type: GrantFiled: May 13, 2011Date of Patent: May 20, 2014Assignee: University of Georgia Research Foundation, Inc.Inventors: Egbert Mundt, Holly S. Sellers, Guillermo Zavala
-
Patent number: 8728487Abstract: The present disclosure provides an attenuated live vaccine strain and the formulations thereof, for preventing pigs from infection of porcine reproductive and respiratory syndrome (PRRS). The preparation methods for the vaccines and the formulations are also provided. The attenuated live vaccine strain provided herein offers significant immunological protection to pigs against PRRS. The vaccine formulations of the present disclosure also have advantages in long shelf lives as well as good stability during storage.Type: GrantFiled: January 20, 2011Date of Patent: May 20, 2014Inventors: Hua Wu, Xue Leng, Zhenguang Li, Fengxue Wang
-
Publication number: 20140134604Abstract: Replicons of genotype 6 hepatitis C virus (HCV) are provided. These replicons contain adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 6 replicons and methods of using these replicons to screen antiviral agents are also provided.Type: ApplicationFiled: November 6, 2013Publication date: May 15, 2014Inventors: Guofeng Cheng, William E. Delaney, IV, Betty Peng, Mei Yu
-
Publication number: 20140134209Abstract: The invention relates to a method for producing a modified viral strain of a virus which is a member of the Reoviridae family and, in particular, relates to vaccinal viral strains of the Orbivirus genus.Type: ApplicationFiled: January 28, 2014Publication date: May 15, 2014Applicant: London School of Hygiene & Tropical MedicineInventors: Polly Roy, Mark Boyce
-
Publication number: 20140135384Abstract: HERV-K human endogenous retroviruses show up-regulated expression in tumors. In particular, splicing events in the env region generate a series of transcripts which utilize the +2 reading frame, relative to the env reading frame. The proteins show activity typical of transcriptional regulators, and they also have oncogenic potential. Two related proteins, PCAP2 and PCAP3, are strongly associated with breast cancer and prostate cancer, respectively. PCAP4 stimulates cell division. These proteins can be used in cancer diagnosis and therapy, and are also drug targets e.g. for adjuvant therapy. The identification of these splice products is remarkable because full sequence information has been available for HERV-K viruses since 1986.Type: ApplicationFiled: January 15, 2014Publication date: May 15, 2014Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC.Inventors: Pablo GARCIA, Stephen F. HARDY, Lewis T. WILLIAMS, Jaime ESCOBEDO
-
Publication number: 20140134204Abstract: The present invention provides a process called “Immune Banking” that enhances vaccine efficacy by exploiting existing humoral responses. The process involves tagging new antigens with molecular markers recognized by an existing antibody response. This recognition of the tagged vaccine components enhances adaptive immune responses to the new vaccine.Type: ApplicationFiled: April 4, 2012Publication date: May 15, 2014Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Gail Bishop, Tony Vanden Bush
-
Publication number: 20140127248Abstract: Described herein is the generation of optimized H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H1N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on selected H1N1 viruses isolated from 1918-2011. Provided herein are optimized H1N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.Type: ApplicationFiled: June 20, 2012Publication date: May 8, 2014Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Ted M. Ross, Brendan M. Giles, Corey J. Crevar
-
Publication number: 20140127264Abstract: The present invention relates to Infectious bronchitis virus (IBV) spike protein or a fragment thereof comprising a receptor-binding domain, wherein said spike protein or said fragment thereof is C-terminally fused to a trimerisation or tetramerisation domain. Such proteins form trimer or tetramer structures and as such they mimic the natural context of the spike protein. The present invention further relates to subunit vaccines comprising such a protein, to DNA molecules encoding such proteins, to plasmids comprising such DNA molecules, to avian live recombinant carrier viruses (LRCV's) comprising such DNA molecules or plasmids, to vaccines comprising such DNA molecules, plasmids and LRCV's and to combination vaccines comprising an IBV spike protein, DNA molecules, plasmids or LRCV's encoding such a protein, and another IBV vaccine capable of inducing protection against another IBV serotype and/or a vaccine capable of inducing protection against another avian pathogen.Type: ApplicationFiled: March 1, 2012Publication date: May 8, 2014Inventors: Hèélne Verheije, Carla Christina Schrier
-
Publication number: 20140128447Abstract: The invention is directed to immunogenic compositions and methods for inducing an immune response against Non-Primate Hepacivirus in an animal. In another aspect, the invention relates to antibodies that bind Non-Primate Hepacivirus polypeptides. In yet another aspect, the invention relates to methods for preventing, or reducing NPHV infection in an animal.Type: ApplicationFiled: May 29, 2013Publication date: May 8, 2014Applicant: The Trustees Of Columbia University In The City Of New YorkInventors: Amit KAPOOR, W. Ian LIPKIN
-
Publication number: 20140127261Abstract: Mutations in the central monomer contact interface of the flavivirus envelope protein which modulate the infectivity of the flavivirus are made. The mutations decrease the ability of the envelope dimer protein to dissociate.Type: ApplicationFiled: November 7, 2012Publication date: May 8, 2014Applicant: Southern Research InstituteInventor: Vladimir Yamshchikov
-
Patent number: 8715691Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: December 1, 2011Date of Patent: May 6, 2014Assignee: MedImmune, LLCInventor: Hong Jin
-
Patent number: 8715692Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.Type: GrantFiled: December 9, 2009Date of Patent: May 6, 2014Assignee: Novavax, Inc.Inventors: Peter Pushko, Yingyun Wu, Michael Massare, Ye Liu, Gale Smith, Bin Zhou
-
Patent number: 8716461Abstract: The present invention relates to the discovery of a new human parvovirus, methods of detecting the parvovirus and diagnosing parvovirus infection, methods of treating or preventing parvovirus infection, and methods for identifying anti-parvoviral compounds.Type: GrantFiled: May 24, 2005Date of Patent: May 6, 2014Assignee: Blood Systems, Inc.Inventors: Eric L. Delwart, Morris S. Jones
-
Publication number: 20140120133Abstract: The present invention provides vectors that contain and express in vivo the genes encoding VP2 and VP5 of African Horse Sickness Virus or an epitope thereof that elicits an immune response in a horse against African horse sickness virus, compositions comprising said vectors, methods of vaccination against African horse sickness virus, and kits for use with such methods and compositions.Type: ApplicationFiled: October 22, 2013Publication date: May 1, 2014Applicants: MERIAL LIMITED, UNIVERSITY OF PRETORIA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jules Maarten Minke, Jean Christophe Audonnet, Alan John Guthrie, Nigel James Maclachlan, Jiansheng Yao
-
Publication number: 20140120126Abstract: The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses.Type: ApplicationFiled: January 2, 2014Publication date: May 1, 2014Applicants: B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Irun R. Cohen, Bracha Rager-Zisman, Angel Porgador, Johannes Herkel
-
Patent number: 8710207Abstract: The present disclosure relates, in some embodiments, to compositions, organisms, systems, and methods for expressing a gene product in a plant using a expression control sequence (ECS) operable in monocots and/or dicots. For example, (i) an isolated nucleic acid may comprise an ECS (e.g., a sugarcane bacilliform virus promoter) and, optionally, an exogenous nucleic acid (ExNA) operably linked to the ECS; (ii) an expression vector may comprise an ECS; an ExNA; and, optionally, a 3? termination sequence, wherein the ECS has promoter activity sufficient to express the ExNA in at least one monocot and at least one dicot; (iii) a microorganism, plant cell, or plant may comprise an isolated nucleic acid; (iv) a method for constitutively expressing an ExNA in a plant (e.g.Type: GrantFiled: May 10, 2011Date of Patent: April 29, 2014Assignee: The Texas A&M University SystemsInventors: T. Erik Mirkov, Jong Won Park, San-Ji Gao
-
Publication number: 20140112923Abstract: Disclosed are an epitope specific to hepatitis B virus (HBV) and use thereof. The disclosed epitope is a conservative position on which mutagenesis does not occur and, therefore, a composition including an antibody to the foregoing epitope or a vaccine composition including the epitope has very low possibility of causing degradation of curing efficacy due to HBV mutation, thus being very useful for HBV treatment.Type: ApplicationFiled: July 25, 2011Publication date: April 24, 2014Applicant: GREEN CROSS CORPORATIONInventors: Se-Ho Kim, Kwang-Won Hong, Yong-Won Shin, Ki Hwan Chang, Min-Soo Kim, Jung-Ae Im
-
Publication number: 20140106340Abstract: Provided herein are new methods, primers, and kits for genotyping HIV-1, including group M viral strains. The methods can be used for HIV-1 drug resistance surveillance and monitoring, for example in resource-poor countries. The disclosed methods can detected more mixed HIV-1 population than previous methods. Given the high efficiency in genotyping diverse HIV-1 group M viral strains from plasma and dried blood spot (DBS) samples and substantial reagent cost saving, the disclosed methods can be used for HIV-1 drug resistance genotyping in both antiretroviral therapy (ART)-naive and -experienced populations for surveillance purposes and patient monitoring.Type: ApplicationFiled: July 5, 2012Publication date: April 17, 2014Applicants: Health and Human ServicesInventors: Chunfu Yang, Zhiyong Zhou, Nicholas Wagar, Joshua R. DeVos
-
Publication number: 20140107014Abstract: The present invention provides compositions, compounds, and methods relating to recombinant adenoviral-based polypeptides for treating disorders associated with epithelial tissues.Type: ApplicationFiled: October 29, 2013Publication date: April 17, 2014Applicant: University of Washington through its Center for CommercializationInventors: Andre Lieber, Hongjie Wang
-
Publication number: 20140106982Abstract: The present invention relates to a system and method for controlling peptide display valency on virus-like particles (VLPs), especially including MS2 or PP7 VLPs. In this method, large amounts of wild-type and low quantities of single-chain dimer coat proteins may be produced from a single RNA. Valency is controlled in immunogen (vaccine) production by providing a system that allows the production of large amounts of wild-type and low quantities of single-chain dimer coating proteins from a single RNA, allowing facile adjustment of display valency levels on bacteriophage VLPs, especially MS2 or PP7 VLPs over a wide range, from few than one—on average—to as many as ninety per particle. This facilitates the production of immunogens and vaccines, including VLPs exhibiting low valency.Type: ApplicationFiled: December 12, 2013Publication date: April 17, 2014Inventors: David S. Peabody, Bryce Chackerian
-
Publication number: 20140105931Abstract: This disclosure relates to viral particles and nucleic acids encoding an HCV envelope glycoprotein 2 containing a mutation. Viral particles can be created and administered to a subject to illicit an immune response.Type: ApplicationFiled: May 18, 2012Publication date: April 17, 2014Applicant: EMORY UNIVERSITYInventor: Arash Grakoui
-
Patent number: 8697417Abstract: The present invention relates to production of proteins in insect cells whereby repeated coding sequences are used in baculoviral vectors. In particular the invention relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral rep proteins that increase the productivity of parvoviral vectors.Type: GrantFiled: July 25, 2008Date of Patent: April 15, 2014Assignee: Uniqure IP B.V.Inventors: Andrew Christian Bakker, Wilhelmus Theodorus Johannes Maria Christiaan Hermens
-
Publication number: 20140099299Abstract: The present invention provides methods and compositions for treating and/or preventing a cytomegalovirus infection in a subject, comprising administering to the subject an effective amount of a cytomegalovirus IL-10 protein modified to have reduced functional activity while retaining immunogenicity. The present invention further provides nucleic acid molecules encoding a cytomegalovirus IL-10 protein or fragment thereof of this invention as well as vectors comprising such nucleic acids. Also provided herein are neutralizing antibodies that specifically bind cmvIL-10.Type: ApplicationFiled: March 27, 2012Publication date: April 10, 2014Applicant: UAB Research FoundationInventors: Mark R. Walter, Peter A. Barry
-
Patent number: 8691961Abstract: The present invention relates to the production and uses of flavivirus replicons and flavivirus particles and reporter virus particles. The present invention relates to the production and uses of chimeric and codon-optimized flavivirus virus replicons and flavivirus virus particles and reporter virus particles.Type: GrantFiled: November 9, 2010Date of Patent: April 8, 2014Assignee: Integral Molecular, Inc.Inventors: Bridget Puffer, Kimberly-Anne Mattia
-
Patent number: 8691563Abstract: Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.Type: GrantFiled: July 17, 2009Date of Patent: April 8, 2014Assignee: Medigen, Inc.Inventors: Peter Pushko, Igor Lukashevich
-
Patent number: 8691505Abstract: The problem to be solved by the present invention is to provide a highly-efficient transformation technology, specifically, a highly-efficient promoter used for transforming algae, a vector comprising the promoter, and a method for transforming algae by using the vector. The promoter according to the present invention is characterized in comprising a polynucleotide constituting a non-coding region located upstream of a gene encoding a structural protein of a ClorDNA virus, and the like.Type: GrantFiled: February 10, 2011Date of Patent: April 8, 2014Assignee: Kochi UniversityInventors: Masao Adachi, Takuma Okami, Keizo Nagasaki, Yuji Tomaru
-
Publication number: 20140093528Abstract: Disclosed herein are isolated immunogens including variant gp120 polypeptides. In an example, a variant gp120 polypeptide includes a deletion of at least 8 consecutive residues of the fourth conserved loop (C4) between residues 419 and 434 of gp120 according to HXB2 numbering. Also provided are isolated nucleic acid molecules encoding the disclosed isolated immunogens. In an example, an isolated nucleic acid molecule further includes a nucleic acid molecule encoding a hepatitis B surface antigen or a variant thereof. Compositions including the isolated immunogens including variant gp120 polypeptides are also disclosed. In some examples, a composition further includes a carrier protein, such as a hepatitis B surface antigen or a variant thereof (natural or recombinant). Viral-like particles are also provided including any of the disclosed isolated immunogens or compositions.Type: ApplicationFiled: November 25, 2013Publication date: April 3, 2014Applicant: The United States of America, as Represented by the Secretary, Dept. of Health & Human ServiceInventor: Ira Berkower
-
Publication number: 20140093556Abstract: The disclosure relates to immunological compositions for vaccinating human beings against infection by the Human Immunodeficiency Virus (HIV).Type: ApplicationFiled: January 26, 2012Publication date: April 3, 2014Applicants: SANOFI PASTEUR SA, POLYMUNE SCIENTIFIC IMMUNOBIOLOGISCHE FORSCHUNG GMBH, UNIVERSIDAD DE GRANADA, PX' THERAPEUTICSInventors: Francisco Conejero-Lara, Irene Luque, Pedro Luis Mateo, Andreas Wagner, Raphaelle Claude, Marie-Gaelle Roger, Nicolas Mouz, Christophe Martin
-
Patent number: 8685409Abstract: There is provided a T cell-based universal influenza vaccine including internal genes capable of preparing against infection by broad hetero-subtypic influenza viruses, and thereby preparing for unpredictable epidemic influenza. The present invention selected internal genes of the consensus sequence obtained from bird, pig, and human influenza isolates in order to develop the T cell-based universal flu vaccine. The T cell-based universal flu vaccine according to the present invention is characterized by including at least one CTL epitope, by containing a plurality of internal genes and using the entire sequence of the internal gene itself. The T cell-based universal flu vaccine can achieve broad defense in infection with hetero-subtypic influenza viruses.Type: GrantFiled: November 1, 2012Date of Patent: April 1, 2014Assignee: Mogam Biotechnology Research InstituteInventors: Jin-Won Youn, Ji-Sun Kwon, Jung-Soon Yoon, Yeon-Jung Kim
-
Patent number: 8685405Abstract: Plants are produced that express an amino acid sequence that, when administered to a fish, produce an antigenic or immune response in the fish. The amino acid sequence in one embodiment is an antigen from an organism that causes pathology in fish. The plant tissue may be fed to the fish, or mixed with other materials and fed to fish, or extracted and administered to the fish.Type: GrantFiled: March 14, 2012Date of Patent: April 1, 2014Assignees: ProdiGene, Inc., Novartis AGInventors: Linda Bootland, Katherine Beifuss
-
Patent number: 8685720Abstract: The present invention provides compositions and methods for programming mammalian cells to perform desired functions. In particular, the present invention provides compositions and methods for programming stem cells to differentiate into a desired cell type. A quorum sensing systems that regulates the expression of cell fate regulators is introduced into mammalian host cells, such as stem cells. The quorum sensing systems generally comprises vectors that express the components of a bacterial quorum sensing pathway, including proteins which catalyze the synthesis of an autoinducer and a gene encoding a regulatory partner of the autoinducer, and vectors in which genes encoding cell fate regulators are operably linked to a promoter induced by the autoinducer/regulatory partner complex.Type: GrantFiled: November 1, 2007Date of Patent: April 1, 2014Assignee: The Trustees of Princeton UniversityInventors: Ron Weiss, Ihor Lemischka, Priscilla E. M. Purnick, Christoph Schaniel, Miles Miller, Patrick Guye
-
Publication number: 20140086947Abstract: Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects.Type: ApplicationFiled: May 16, 2013Publication date: March 27, 2014Applicant: IMMUNE DESIGN CORP.Inventor: IMMUNE DESIGN CORP.
-
Publication number: 20140086953Abstract: Novel attenuating deletions of Chikungunya virus E2 polypeptides are provided as are attenuated viruses comprising the deletions. Also provided are immunogenic compositions comprising the attenuated viruses and methods of producing such viruses in cells (such as insect cells). Viruses of the embodiments can be used for immunization of animals to provide protection from the pathogenic effects of Chikungunya virus infection.Type: ApplicationFiled: September 26, 2013Publication date: March 27, 2014Applicant: Research Development FoundationInventors: Dennis T. BROWN, Raquel HERNANDEZ